COMPANY PROFILE

Dispatch Bio

Explore full profile

Cloud-powered platform for infectious disease diagnostics

Philadelphia, United StatesFounded 2022Health

Valuation $1–2.5B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Dispatch Bio

Dispatch Bio is a technology company focused on infectious disease diagnostics. Founded in 2021 by CEO Byron Elton, the company aims to modernize diagnostic testing by providing a cloud-based software platform. This platform is designed to connect patients, providers, and laboratories to deliver faster and more accurate infectious disease test results.

The core of Dispatch Bio's offering is its proprietary software that integrates various stages of the diagnostic process. For laboratories, it provides a system to manage test orders, workflows, and results reporting. For healthcare providers, it offers a streamlined way to order tests and receive timely, actionable results for their patients. This integration is intended to reduce the turnaround time for diagnoses, a critical factor in managing infectious diseases effectively. The company's business model appears to be B2B, targeting diagnostic labs and healthcare providers with its software-as-a-service (SaaS) platform.

The company is in its early stages, having been established in 2021, and is based in the United States. While specific details about funding rounds are not prominently published, its focus on applying cloud technology to the diagnostics market positions it within the growing digital health and healthtech sectors. The platform emphasizes security and compliance, which are crucial when handling sensitive patient data.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Philadelphia, United States
Employees: 65
Open positions: 9
Dealroom signal: 59.9/100
Industry: Health
Sector: Health, Infections and Infectious Diseases, Spinout, Rumoured $1B, Health It, medical testing
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jul 2025	$216M	$864M	Stanford University · University of Pennsylvania · ARCH Venture Partners · Bristol-Myers Squibb	↗
SEEDOther financing	Jan 2023	—	—	Undisclosed	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Dispatch Bio website traffic

Latest recorded traffic for Dispatch Bio is 3.8K monthly website visits, up 15.2% over the last three months.

Latest monthly visits3.8K 3-month web change+15.2%

Monthly website visitsJul 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

(Executive) Director, Regulatory Affairs, CMCSan Francisco, California, United States, Northern America, Americas · Other · Sep 2, 2026 (Executive) Director, Regulatory Affairs, CMCPhiladelphia, PA · Other · Aug 25, 2026 Associate Scientist/Scientist I, Cell Analytical DevelopmentPhiladelphia, Pennsylvania, United States, Northern America, Americas · Other · Aug 19, 2026 Senior Associate/Manager, Regulatory AffairsSan Francisco, California, United States, Northern America, Americas · Legal · Aug 19, 2026 Associate Scientist/Scientist I, Cell Analytical Product SciencesPhiladelphia, Pennsylvania, United States, Northern America, Americas · Other · Aug 19, 2026 Director, IT & Business EnablementPhiladelphia, PA · Business Development · Aug 11, 2026 Senior Scientist, Upstream Viral Process DevelopmentPhiladelphia, Pennsylvania, United States, Northern America, Americas · Other · Aug 5, 2026 Associate Director, Clinical OperationsSan Francisco, California, United States, Northern America, Americas · Other · Jul 22, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ACACTOSensElectrochemical biosensors for rapid STI detection.	Brno, Czechia	Operational	2	—	—
ABAUISET BiotechnologyAIE-based in-vitro diagnostic and rapid test solutions.	Sha Tin District, Hong Kong	Operational
ASAstratusRapid antimicrobial susceptibility testing platform for diagnostics.	Reading, United Kingdom	Operational
CACAS-EnvisionThird-generation digital PCR and medical chip development.	Shenzhen, China	Operational
CACASBIOCRISPR-Cas gene therapies and point-of-care diagnostics	Australia	Operational
ESEspiraMicrofluidics-based diagnostic tools for clinical and environmental applications	Salt Lake City, United States	Operational
UTUltrabio TechnologiesQPCR assay kits for HIV-1 DNA research	Bothell, United States	Operational
ALAdvanced Biological LaboratoriesInfectious disease diagnostic and medical software solutions	Luxembourg, Luxembourg	Operational